Key result
HDAC3 inhibition reduces ischemia-reperfusion injury in rats by elevating miR-19a-3p and reducing CDK2.
Why the study?
The study focused on the effect of miR-19a-3p and HDAC3 in myocardial ischemia-reperfusion injury by targeting cyclin-dependent kinase 2.
Does inhibition of HDAC3 ameliorate myocardial ischemia-reperfusion injury in a rat model?
Does inhibition of HDAC3 ameliorate myocardial ischemia-reperfusion injury in a rat model?
Inhibition of HDAC3 ameliorates myocardial ischemia-reperfusion injury in rats by upregulating miR-19a-3p and reducing CDK2.
Should not change clinical practice; hypothesis-generating for HDAC3 inhibition in myocardial ischemia-reperfusion injury.
OBJECTIVE: Over the years, the roles of microRNAs (miRNAs) and histone deacetylase 3 (HDAC3) in human diseases have been investigated. This study focused on the effect of miR-19a-3p and HDAC3 in myocardial ischemia-reperfusion (I/R) injury (MIRI) by targeting cyclin-dependent kinase 2 (CDK2). METHODS: The I/R rat models were established by coronary artery ligation, which were then treated with RGFP966 (an inhibitor of HDAC3), miR-19a-3p agomir or antagomir, or silenced CDK2 to explore their roles in the cardiac function, pathological changes of myocardial tissues, myocardial infarction area, inflammatory factors and oxidative stress factors in rats with MIRI. The expression of miR-19a-3p, HDAC3, and CDK2 was determined by RT-qPCR and western blot assay, and the interaction among which was also verified by online prediction, luciferase activity assay and ChIP assay. RESULTS: The results indicated that HDAC3 and CDK2 were upregulated while miR-19a-3p was downregulated in myocardial tissues of I/R rats. The inhibited HDAC3/CDK2 or elevated miR-19a-3p could promote cardiac function, attenuate pathological changes, inflammatory reaction, oxidative stress, myocardial infarction area and apoptosis of myocardial tissues. HDAC3 mediates miR-19a-3p and CDK2 is targeted by miR-19a-3p. CONCLUSION: Inhibited HDAC3 ameliorates MIRI in a rat model by elevating miR-19a-3p and reducing CDK2, which may contribute to the treatment of MIRI.
No takes yet. Share an insight, caveat, or question.
Song et al. (2020) studied Myocardial ischemia-reperfusion injury. RGFP966 (HDAC3 inhibitor), miR-19a-3p agomir or antagomir, or silenced CDK2 was evaluated on Cardiac function, pathological changes, myocardial infarction area, inflammatory factors, oxidative stress, and apoptosis. Inhibiting HDAC3 ameliorated myocardial ischemia-reperfusion injury in a rat model by elevating miR-19a-3p and reducing CDK2, which improved cardiac function and reduced infarct area.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: